发明名称 RNA antagonist compounds for the modulation of PIK3CA expression
摘要 The invention relates to oligomeric compounds (oligomers), which target PIK3CA mRNA in a cell, leading to reduced expression of PIK3CA. Reduction of PIK3CA expression is beneficial for the treatment of certain medical disorders, such as hyperproliferative diseases (e.g., cancer). The invention provides therapeutic compositions that include the oligomers and methods for modulating the expression of PIK3CA using said oligomers, including methods of treatment.
申请公布号 US7863437(B2) 申请公布日期 2011.01.04
申请号 US20080323744 申请日期 2008.11.26
申请人 ENZON PHARMACEUTICALS, INC.;SANTARIS PHARMA A/S 发明人 HEDTJARN MAJ
分类号 C07H21/04;C12N15/113 主分类号 C07H21/04
代理机构 代理人
主权项
地址